Data evaluated the use of the CAVT technology in people with intermediate-risk pulmonary embolism (PE). Results showed that those treated with CAVT had shorter hospital stay lengths, shorter post-procedure stay length and fewer complications when compared to other treatment options. Additionally, CAVT produced low in-hospital mortality, with no significant difference between treatment options.
Dr. Parag J. Patel presented the data at the Vascular Interventional Advances (VIVA) 2024 Conference in Las Vegas.
“This first-of-a-kind analysis demonstrates that patients treated with CAVT utilized fewer hospital resources,” said Patel. “These findings, as well as recent studies which show CAVT’s positive impact on patient outcomes, strongly showcase the significant benefits of CAVT over other treatment options for PE. We will continue to see the growing adoption of CAVT as a frontline therapy given the notable beneficial impact on patients and the overall health system.”
More on the findings from the Penumbra study
The retrospective study utilized the Vizient Clinical Data Base to identify 2,060 adult inpatients with intermediate-risk PE. Its 1:1 propensity score matched analysis included resource use and health outcomes among patients in the U.S. treated with the Penumbra Lightning Flash or Lightning 12 technology. It compared those to patients treated with anticoagulation, catheter directed thrombolysis or other mechanical thrombectomy devices.
Findings included CAVT leading to 25%-35% shorter total hospital length of stay. Additionally, investigators reported a 25%-30% higher average rate of patients discharged home. Those who received CAVT registered 2-3 times fewer average composite complications.
In the study, investigators found CAVT associated with improvements in contribution margin relative to anticoagulation alone.
“CAVT will continue to redefine the way physicians treat symptomatic PE. We have a growing body of evidence that demonstrates the meaningful benefits of CAVT on patient outcomes,” said Dr. James F. Benenati, chief medical officer at Penumbra. “Now with this study, the findings suggest that by increasing patient access to advanced therapies like CAVT, it can also have an important, positive impact on hospital systems by greatly reducing resource utilization versus other modalities, therefore decreasing the overall cost to the healthcare system.”
